ArticleAnnals of hematology2026

Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial.

Lars Fransecky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.